- $34.87m
- -$145.60m
- $31.37m
EyePoint Pharmaceuticals Inc expected to post a loss of 80 cents a share - Earnings Preview
Brief: Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration
Brief: Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
EyePoint Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
EyePoint Pharmaceuticals Inc expected to post a loss of 66 cents a share - Earnings Preview
Brief: Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
EyePoint Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-Alphabet, Ford Motor, New York Times
U.S. STOCKS ON THE MOVE-Walt Disney, Fiserv, Old Dominion
EyePoint Pharma rises on eye disease drug trial data
Brief: EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
Brief: Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule
U.S. RESEARCH ROUNDUP-Cable One, Neurogene, Topbuild
Brief: EyePoint Pharmaceuticals Reports Q3 2024 Financial Results And Highlights Recent Corporate Developments
EyePoint Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview
Brief: Eyepoint Pharmaceuticals Prices Public Offering Of 12.7 Mln Shares At $11.00 Each
EyePoint slides after unveiling $100 mln stock offering
U.S. STOCKS ON THE MOVE-Monte Rosa, EyePoint Pharma, Shake Shack
EyePoint rises after positive data from eye disease drug trial